Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22049118 | 0.79 | MEN1 (0.30) | — | |
| SCHEMBL11534893 | 0.79 | — | — | |
| SCHEMBL2047727 | 0.73 | — | — | |
| SCHEMBL142354 | 0.73 | — | — | |
| SCHEMBL2046306 | 0.69 | — | — | |
| SCHEMBL23259994 | 0.67 | — | — | |
| SCHEMBL9507188 | 0.67 | — | — | |
| SCHEMBL468366 | 0.67 | ALDH1A1 (0.36) | TDP1 | |
| SCHEMBL581530 | 0.64 | PDE10A (0.33) | TDP1 | |
| SCHEMBL9647771 | 0.64 | ALDH1A1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-62195308-A | — | — | None | — | — | JP | disclosed |
| JP-5155859-A | — | — | None | — | — | JP | disclosed |
| JP-5155861-A | — | — | None | — | — | JP | disclosed |
| JP-5155860-A | — | — | None | — | — | JP | disclosed |
| JP-11029407-A | — | — | None | — | — | JP | disclosed |
| JP-61145103-A | — | — | None | — | — | JP | disclosed |
| EP-3630770-B1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | RELAY THERAPEUTICS INC (US) | 2024-08-28 | — | — | EP | disclosed |
| EP-4291565-A1 | SYNTHETIC CINCHONA ALKALOIDS AGAINST CANCER | Ares Pharmaceuticals, LLC (US) | 2023-12-20 | — | — | EP | disclosed |
| US-11591336-B2 | Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors | D. E. SHAW RESEARCH, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| US-11066421-B1 | Synthetic cinchona alkaloids against cancer | Ares Pharmaceuticals, LLC (US) | 2021-07-20 | — | — | US | disclosed |
| US-4083713-A | CONTROLLING WEEDS | ROHM AND HAAS COMPANY (US) | 1978-04-11 | — | — | US | disclosed |
| US-RE29585-E | DYEING WOOL | CIBA-GEIGY CORPORATION (US) | 1978-03-21 | — | — | US | disclosed |
| US-4067864-A | FOR CELLULOSE OR POLYAMIDES | CIBA-GEIGY AG (CH) | 1978-01-10 | — | — | US | disclosed |
| US-4049661-A | FIBER-REACTIVE | CIBA-GEIGY AG (CH) | 1977-09-20 | — | — | US | disclosed |
| US-4039523-A | YELLOW | CIBA-GEIGY AG (CH) | 1977-08-02 | — | — | US | disclosed |
| US-4017477-A | 3-Halogeno-6-hydroxy-pyridone-(2) azo dyestuffs | CIBA-GEIGY AG (CH) | 1977-04-12 | — | — | US | disclosed |
| US-4001203-A | Heavy metal complexes of azo dyestuffs containing a heterocyclic diazo component and the residue of 5-halogeno-2,3-dihydrozypyridine as coupling component | CIBA-GEIGY AG (CH) | 1977-01-04 | — | — | US | disclosed |
| US-4001205-A | WATER-SOLUBLE, FIBER-REACTIVE PHENYLAZODIHYDROXY, METHYL, CYANOPYRIDINE DYESTUFFS | CIBA-GEIGY AG (CH) | 1977-01-04 | — | — | US | disclosed |
| US-3971738-A | Heavy metal complexes of azo compounds containing a halogeno-2,3-dihydroxy pyridine coupling component | CIBA-GEIGY AG (CH) | 1976-07-27 | — | — | US | disclosed |
| US-3956263-A | 4-Methyl-2,6-dihydroxy-3-cyanopyridine containing dyestuffs | CIBA-GEIGY AG (CH) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066421-B1 | Synthetic cinchona alkaloids against cancer | UACA, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GDA | TDP1 1002/4885 |
| US-11591336-B2 | Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors | PTPN5, PTPN2, PTPN1 | TDP1 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.